Myriad Genetics (MYGN) PT Raised to $40 at Leerink Partners
Tweet Send to a Friend
Leerink Partners analyst Puneet Souda raised the price target on Myriad Genetics (NASDAQ: MYGN) to $40.00 (from $35.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
